Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Therapeutics (CTIC) -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (394)	2/2/2005 8:23:58 AM
From: Icebrg	Read Replies (1) \| Respond to of 946

I suppose it was more than a coincidence that first Stellar 3 was unblinded and then the management decide to award itself with up to 100.000 free shares. Sleazy. The free shares, I am referring to. Were the options they have taken over the years not enough? The calculation might be that in the face of positive Stellar results criticism will be somewhat dull. Even if no results will be available for some time, I guess it should be possible in a couple of days time to get a rough idea about how things are going. Especially, if results are as good as a comparison with historical data appear to indicate. (Remember that the trial is unblinded. Participating centers know which patients got Xyotax and who got control). Erik

To: Icebrg who wrote (394)	2/2/2005 11:04:14 AM
From: Icebrg	Read Replies (1) \| Respond to of 946

The real sleaze here is of course not the 50 % which vest upon FDA's approval of Xyotax. It is the 50% which vest following the achievement of a specific performance event. In the first case there is at least a certain level of alignment between the interests of shareholders and management. But the other 50 %? Are they going to receive 50.000 shares for what appears to amount to doing their jobs in a proper way? That is really, really outrageous. Erik